Cas no 96829-58-2 (Orlistat)

Orlistat is a lipase inhibitor that reduces fat absorption in the gastrointestinal tract by inhibiting pancreatic lipase activity. This results in significant weight loss and improved glycemic control in obese individuals. Orlistat's efficacy stems from its high specificity for pancreatic lipase, minimizing off-target effects on other enzymes or biological systems.
Orlistat structure
Orlistat structure
Product Name:Orlistat
CAS No:96829-58-2
MF:C29H53NO5
MW:495.73482966423
MDL:MFCD05662360
CID:61866
PubChem ID:3034010
Update Time:2025-07-30

Orlistat Chemical and Physical Properties

Names and Identifiers

    • Orlistat
    • N-FORMYL-L-LEUCINE (1S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]DODECYL ESTER
    • RO-18-0647
    • (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER
    • (-)-TETRAHYDROLIPSTATIN
    • XENICAL
    • (-)-Tetrahydrolipstatin(EquivalentToOrlistat)
    • Orlipastat
    • Xenical, (-)-Tetrahydrolipstatin, N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl Ester,
    • Orlistat, Tetrahydolipstat
    • ORLIPASTATUM
    • (-)-Tetrahydrolipstatin, Ro-18-0647, N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
    • L-Leucine, N-formyl-, (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
    • N-Formyl-L-leucine (1S)-1-[[(2S)-3α-hexyl-4-oxooxetan-2β-yl]methyl]dodecyl ester
    • N-Formyl-L-leucine (S)-1-[[(2S)-3α-hexyl-4-oxooxetane-2β-yl]methyl]dodecyl ester
    • Orlistat Powder
    • (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID
    • [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate
    • 002
    • Alli
    • Ro 18-0647
    • Tetrahydrolipstatin
    • THLP
    • (?)-Tetrahydrolipstatin
    • Orlipastatum [INN-Latin]
    • C29H53NO5
    • (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate
    • Orlistat (Alli, Xenical)
    • MLS002207022
    • N-Formyl-L-le
    • L-Leucine, N-formyl-, 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester, [2S-[2α(R*),3β]]- (ZCI)
    • L
    • Listata
    • Ro 18-0647/002
    • 96829-58-2
    • MLS001423955
    • ORLISTAT [MART.]
    • NCGC00165856-14
    • SW197481-2
    • NSC 758881
    • NCGC00165856-15
    • AHLBNYSZXLDEJQ-FWEHEUNISA-N
    • HSDB 7556
    • Orlistat (Standard)
    • Tox21_111437_1
    • R-212
    • ORLISTAT [JAN]
    • N-formyl-L-leucine (1S)-1-{[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl}dodecyl ester
    • SR-01000759417
    • HMS3413P06
    • BRD-K63343048-001-12-2
    • Ro18-0647
    • DB01083
    • N-formyl-L-leucine-(S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]-dodecyl ester
    • Ro-18-0647/002
    • UNII-95M8R751W8
    • HMS3677P06
    • N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone
    • ORLISTAT [INN]
    • s1629
    • Q424163
    • Q-201519
    • HMS2051I08
    • (-)-tetrahydrolipostatin
    • N-formyl-L-leucine (S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
    • 95M8R751W8
    • tetrahydrolipastatin
    • AB00639987-09
    • CHEBI:94686
    • ORLISTAT [USP-RS]
    • ORLISTAT [ORANGE BOOK]
    • CCG-100851
    • SMR000466339
    • NC00101
    • (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl N-formyl-L-leucinate
    • MFCD05662360
    • HY-B0218R
    • NCGC00165856-01
    • DTXCID40820067
    • O0381
    • CAS-96829-58-2
    • ORLISTAT [VANDF]
    • CS-0694775
    • L-Leucine, N-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2S-(2alpha(R*),3beta))-
    • EN300-268136
    • Orlistat, >=98%, solid
    • BDBM24567
    • 104872-04-0
    • Ro-180647002
    • BIDD:GT0853
    • NCGC00095128-01
    • Tetrahydrolipstatin;Ro-18-0647
    • BCP0726000044
    • DTXSID8023395
    • NCGC00165856-03
    • Ro-180647-002
    • Orlistat [USAN:INN:BAN]
    • L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester
    • Xenical (TN)
    • ORLISTAT [WHO-DD]
    • (-)-Tetrahydrolipstatin; Orlistat; Ro 18-0647/002; Tetrahydrolipstatin; Xenical; L-Leucine, N-formyl-, 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester, [2S-[2alpha(R*),3beta]]-
    • SR-01000759417-5
    • SCHEMBL16408
    • ORLISTAT [EMA EPAR]
    • ORLISTAT [MI]
    • [(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-oxetan-2-yl]methyl]dodecyl] (2S)-2-formamido-4-methyl-pentanoate
    • HB4009
    • BRD-K63343048-001-13-0
    • MLS000759448
    • BO164179
    • NCGC00165856-02
    • HY-B0218
    • [(2S)-1-[(2R,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2R)-2-formamido-4-methylpentanoate
    • Tox21_111437
    • SR-01000759417-7
    • CHEMBL175247
    • AB00639987_10
    • NS00004788
    • 2-formamido-3-[(3-hexyl-4-oxo-oxetan-2-yl)methyl]-2-isobutyl-tetradecanoate
    • GTPL5277
    • D04028
    • Lipase Inhibitor, THL
    • ORLISTAT [HSDB]
    • BCP9001031
    • L-LEUCINE, N-FORMYL-, 1-((3-HEXYL-4-OXO-2-OXETANYL)METHYL)DODECYL ESTER, (2S-(2.ALPHA.(R*),3.BETA.))-
    • ORLISTAT [USP MONOGRAPH]
    • THL
    • Z2379810072
    • NSC-758881
    • orlistatum
    • Orlistat (JAN/USP/INN)
    • R212
    • ORLISTAT [USAN]
    • (2S)-2-formamido-4-methylpentanoic acid [(2S)-1-[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]tridecan-2-yl] ester
    • Orlistat, United States Pharmacopeia (USP) Reference Standard
    • KS-1183
    • AKOS015894875
    • (S)-((S)-1-((2S,3S)-3-hexyl-4-oxooxetan-2-yl)tridecan-2-yl) 2-formamido-4-methylpentanoate
    • Orlistat, Pharmaceutical Secondary Standard; Certified Reference Material
    • MDL： MFCD05662360
    • Inchi： 1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1
    • InChI Key： AHLBNYSZXLDEJQ-FWEHEUNISA-N
    • SMILES： C([C@@H]1OC(=O)[C@H]1CCCCCC)[C@H](CCCCCCCCCCC)OC(=O)[C@@H](NC=O)CC(C)C
    • BRN： 3658031

Computed Properties

  • Exact Mass: 495.39200
  • Monoisotopic Mass: 495.392
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 5
  • Heavy Atom Count: 35
  • Rotatable Bond Count: 23
  • Complexity: 579
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 4
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 81.7
  • XLogP3: 10

Experimental Properties

  • Color/Form: White crystalline powder
  • Density: 0.976
  • Melting Point: 43.0 to 47.0 deg-C
  • Boiling Point: 615.9°C at 760 mmHg
  • Flash Point: 326.3 oC
  • Refractive Index: 1.469
  • Solubility: DMSO: 19?mg/mL
  • PSA: 81.70000
  • LogP: 7.90870
  • Merck: 6869
  • Specific Rotation: -33 - -36° (c=1, CHCl3)

Orlistat Security Information

Orlistat Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.
O0381-1G
Orlistat
 96829-58-2 >97.0%(HPLC)(N)
1g
 ￥790.00 2024-04-15
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
O159936-100mg
Orlistat
 96829-58-2 >97.0%(HPLC)
100mg
 ￥29.90 2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
O159936-250mg
Orlistat
 96829-58-2 >97.0%(HPLC)
250mg
 ￥30.90 2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
O159936-25g
Orlistat
 96829-58-2 >97.0%(HPLC)
25g
 ￥461.90 2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
O159936-1g
Orlistat
 96829-58-2 >97.0%(HPLC)
1g
 ￥74.90 2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
O159936-5g
Orlistat
 96829-58-2 >97.0%(HPLC)
5g
 ￥129.90 2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
O159936-100g
Orlistat
 96829-58-2 >97.0%(HPLC)
100g
 ￥1538.90 2023-09-01
S e l l e c k ZHONG GUO
S1629-10mM (1mL in DMSO)
Orlistat (Ro 18-0647)
 96829-58-2 99.98%
10mM (1mL in DMSO)
 ￥1053.71 2023-09-16
S e l l e c k ZHONG GUO
S1629-25mg
Orlistat (Ro 18-0647)
 96829-58-2 99.98%
25mg
 ￥812.99 2023-09-16
S e l l e c k ZHONG GUO
S1629-100mg
Orlistat (Ro 18-0647)
 96829-58-2 99.98%
100mg
 ￥2187.46 2023-09-16

Orlistat Production Method

Production Method 1

Reaction Conditions
1.1 Reagents: Triphenylphosphine ,  Diisopropyl azodicarboxylate Solvents: Tetrahydrofuran ;  0 °C → rt
Reference
A Concise, Phosphate-Mediated Approach to the Total Synthesis of (-)-Tetrahydrolipstatin
Venukadasula, Phanindra K. M.; Chegondi, Rambabu; Maitra, Soma; Hanson, Paul R., Organic Letters, 2010, 12(7), 1556-1559

Production Method 2

Reaction Conditions
1.1 Solvents: Dichloromethane ;  -10 - -5 °C; 1 h, -5 - 0 °C
1.2 Reagents: Water
Reference
Process for the preparation of orlistat via formylation of amino-orlistat with formic acid anhydride
, World Intellectual Property Organization, , ,

Production Method 3

Reaction Conditions
1.1 Reagents: Hydrazine hydrate (1:1) Catalysts: Iron pentacarbonyl Solvents: Water ;  50 °C; 5 h, 50 °C; 50 °C → rt
1.2 Solvents: Dichloromethane ;  10 - 20 min, rt → 65 °C
Reference
Method for preparing weight-reducing medicine orlistat from lipstatin
, China, , ,

Production Method 4

Reaction Conditions
1.1 Reagents: Tetraphenylporphyrin ,  Diisopropyl azodicarboxylate Solvents: Tetrahydrofuran ;  3 h, 0 °C → rt
Reference
Stereoselective syntheses of (-)-tetrahydrolipstatin via Prins cyclizations
Yadav, J. S.; Reddy, M. Sridhar; Prasad, A. R., Tetrahedron Letters, 2006, 47(29), 4995-4998

Production Method 5

Reaction Conditions
1.1 Reagents: Triphenylphosphine ,  Diisopropyl azodicarboxylate
Reference
Diastereoselective allylations and crotylations under phase-transfer conditions using trifluoroborate salts: an application to the total synthesis of (-)-tetrahydrolipstatin
Thadani, Avinash N.; Batey, Robert A., Tetrahedron Letters, 2003, 44(44), 8051-8055

Production Method 6

Reaction Conditions
1.1 Reagents: Hydrogen Catalysts: Palladium dihydroxide Solvents: Ethanol ;  2 h, rt
1.2 Reagents: Triphenylphosphine ,  Diisopropyl azodicarboxylate Solvents: Toluene ,  Tetrahydrofuran ;  0 °C; 3 h, rt
Reference
MNBA-Mediated β-Lactone Formation: Mechanistic Studies and Application for the Asymmetric Total Synthesis of Tetrahydrolipstatin
Shiina, Isamu; Umezaki, Yuma; Kuroda, Nobutaka; Iizumi, Takashi; Nagai, Shunsuke; et al, Journal of Organic Chemistry, 2012, 77(11), 4885-4901

Production Method 7

Reaction Conditions
1.1 Reagents: [[2,2′-[(1R,2R)-1,2-Cyclohexanediylbis[(nitrilo-κN)methylidyne]]bis[4,6-bis(1,1-… Catalysts: Cuprous chloride Solvents: Acetonitrile ;  15 °C
1.2 Reagents: Sodium borohydride ;  2 - 4 h, 15 °C
1.3 Reagents: Water ;  cooled
Reference
Improved synthetic method of antiobesity agent Orlistat
, China, , ,

Production Method 8

Reaction Conditions
1.1 Reagents: Hydrogen Catalysts: Palladium Solvents: Methanol
Reference
Method for preparing orlistat
, World Intellectual Property Organization, , ,

Production Method 9

Reaction Conditions
1.1 Reagents: Benzenesulfonyl chloride ,  Hydrochloric acid Solvents: 1-Butanol ,  Pyridine ;  rt; 20 h, rt
1.2 Reagents: Hydrogen Catalysts: Palladium Solvents: Tetrahydrofuran ;  18 h, rt → 40 °C
1.3 Reagents: Triphenylphosphine ,  Diisopropyl azodicarboxylate Solvents: Tetrahydrofuran ;  15 h, 0 - 5 °C
Reference
Preparation of orlistat and its intermediate
, China, , ,

Production Method 10

Reaction Conditions
1.1 Reagents: Diisopropyl azodicarboxylate Solvents: Tetrahydrofuran
Reference
Oxazoline N-Oxide-Mediated [2+3] Cycloadditions. Application to a Synthesis of (-)-Tetrahydrolipstatin
Dirat, O.; Kouklovsky, C.; Langlois, Yves, Organic Letters, 1999, 1(5), 753-755

Production Method 11

Reaction Conditions
1.1 Reagents: Triphenylphosphine ,  Diisopropyl azodicarboxylate Solvents: Tetrahydrofuran ;  0 °C; overnight, rt
Reference
A chiron approach to (-)-tetrahydrolipstatin
Yadav, J. S.; Rao, K. Vishweshwar; Prasad, A. R., Synthesis, 2006, (22), 3888-3894

Production Method 12

Reaction Conditions
1.1 Reagents: Triphenylphosphine Solvents: Tetrahydrofuran ;  rt → 0 °C
1.2 Reagents: Azobisisobutyronitrile ;  30 min, 0 °C; 0 °C → rt; 12 h, rt
Reference
Process for preparation of Orlistat and intermediate
, China, , ,

Orlistat Raw materials

Orlistat Preparation Products

Orlistat Suppliers

Suzhou Senfeida Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:96829-58-2)Orlistat
Order Number:sfd5769
Stock Status:in Stock
Quantity:200kg
Purity:99.9%
Pricing Information Last Updated:Friday, 19 July 2024 14:34
Price ($):discuss personally
Amadis Chemical Company Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:96829-58-2)Orlistat
Order Number:A845645
Stock Status:in Stock
Quantity:100g
Purity:99%
Pricing Information Last Updated:Friday, 30 August 2024 07:06
Price ($):325.0
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:96829-58-2)Orlistat
Order Number:LE1312;LE26512725
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 11:40
Price ($):discuss personally

Orlistat Spectrogram

13C NMR
13C NMR
1H NMR 300 MHz DMSO
1H NMR
MS-MS
MS-MS

Orlistat Related Literature

Related Categories

Additional information on Orlistat

Orlistat (CAS No. 96829-58-2): A Comprehensive Guide to Its Properties, Applications, and Market Trends

Orlistat, with the CAS number 96829-58-2, is a well-known pharmaceutical compound primarily used as an anti-obesity medication. This lipase inhibitor has gained significant attention due to its effectiveness in weight management, making it a popular topic in health and wellness discussions. In this article, we will explore the chemical properties of Orlistat, its mechanism of action, therapeutic applications, and current market trends.

The chemical structure of Orlistat is characterized by its ability to bind to pancreatic and gastric lipases, enzymes responsible for breaking down dietary fats. By inhibiting these enzymes, Orlistat prevents the absorption of approximately 30% of dietary fats, which are then excreted unchanged. This unique mechanism has made it a cornerstone in the treatment of obesity, especially when combined with lifestyle modifications.

One of the most frequently asked questions about Orlistat is its safety profile. Clinical studies have shown that while the drug is generally well-tolerated, it may cause gastrointestinal side effects such as oily stools and flatulence. However, these effects are often temporary and can be mitigated by adhering to a low-fat diet. The efficacy of Orlistat in weight loss has been demonstrated in numerous trials, with patients achieving significant reductions in body weight over a 6-12 month period.

In recent years, the demand for Orlistat-based products has surged, driven by the global obesity epidemic and increasing awareness of metabolic health. The compound is available under various brand names, including Xenical and Alli, and is often featured in discussions about non-surgical weight loss solutions. Its over-the-counter availability in some regions has further boosted its popularity among consumers seeking accessible weight management options.

Another hot topic related to Orlistat is its role in managing conditions like type 2 diabetes and hyperlipidemia. Research suggests that the drug not only aids in weight reduction but also improves glycemic control and lipid profiles in obese patients. This dual benefit has positioned Orlistat as a valuable tool in the fight against metabolic syndrome, a cluster of conditions that increase the risk of heart disease and stroke.

The market for Orlistat continues to evolve, with pharmaceutical companies investing in innovative formulations to enhance patient compliance and reduce side effects. For instance, extended-release versions and combination therapies are being explored to improve the drug's overall efficacy. Additionally, the rise of telemedicine and online pharmacies has made Orlistat more accessible to a broader audience, further driving its market growth.

From a regulatory perspective, Orlistat is approved by major health authorities, including the FDA and EMA, underscoring its safety and efficacy. However, it is essential to use the medication under medical supervision, especially for individuals with pre-existing conditions or those taking other medications. The recommended dosage of Orlistat typically ranges from 60 mg to 120 mg, taken with meals containing fats.

In conclusion, Orlistat (CAS No. 96829-58-2) remains a pivotal player in the field of weight management and metabolic health. Its unique mechanism of action, coupled with its proven clinical benefits, makes it a sought-after solution for individuals struggling with obesity. As research continues to uncover new applications and formulations, the future of Orlistat looks promising, offering hope to millions worldwide.

96829-58-2 (Orlistat) Related Products

Recommended suppliers
Suzhou Senfeida Chemical Co., Ltd
(CAS:96829-58-2)Orlistat
sfd5769
Purity:99.9%
Quantity:200kg
Price ($):Inquiry
Email
Amadis Chemical Company Limited
(CAS:96829-58-2)Orlistat
A845645
Purity:99%
Quantity:100g
Price ($):325.0
Email